You searched for "PXF"

100 results found

Interview with Clinical Director of OpenEyes

Professor James Morgan is an Ophthalmic Consultant at Cardiff Hospital and also the clinical director of the OpenEyes programme. Given the national push for electronic records we felt hearing directly from James would be of interest. The interview was conducted...

Semaglutide and vision loss: A new concern for NAION risk?

This article has been verified for CPD. Click the button below to answer a few short questions and download a form to be included in your CPD folder. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have emerged as transformative agents in...

A closer look at the new wave of glaucoma surgery – radical or old school?

Glaucoma is a challenging condition to treat because the exact pathophysiology remains unclear and the only readily modifiable factor is the intraocular pressure (IOP). Additionally, most glaucoma patients are completely asymptomatic, yet are often subjected to lifelong medical therapy. The...

Well-presented scholarly research work will reduce chances of journal rebuttal

Submitting to an academic journal? Are you aware of the requirements and constraints of relevant copyright laws? Rod McNeil provides a guide for aspiring authors. Getting published in peer-reviewed academic and medical journals is not easy. But careful attention to...

Towards virtual reality conferences?

COVID-19 is forcing us to reconsider every aspect of life. The authors ask what future ophthalmic meetings could look like. The coronavirus disease COVID-19 pandemic disrupted ophthalmic conferences resulting in the cancellation of the majority of meetings in 2020, e.g....

Rare eye diseases: progress continues with authorised orphan medicines and breakthrough technologies

An update on the development of orphan medicines, recent regulatory treatment approvals for rare eye conditions and advances in retinal prosthetic technologies for blinding diseases. The prevalence of a rare disease is based usually on a range of estimates and...

Educational concerns and anxiety levels amongst ophthalmology trainees during the COVID-19 pandemic

How concerned are ophthalmology trainees about the present impact and the future consequences of suspended ophthalmic training programmes? Researchers in the West of Scotland investigate. Anxiety, stress and the longer-term stress reaction of burnout often go unrecognised, yet are known...

Update on emerging therapies for age-related macular degeneration

The 23rd European Society of Retina Specialists (EURETINA) Congress, held in Amsterdam, the Netherlands, provided a timely update on anti-complement therapy for geographic atrophy and emerging investigational therapies for neovascular age-related macular degeneration. Anti-complement therapy for geographic atrophy Geographic atrophy...

Collaborating across the Caribbean to tackle diabetic retinopathy

The VISION 2020 LINKS Programme has been running since 2004, with a focus on improving the quality and quantity of eye care training in low-income countries [1]. In 2014, the Diabetic Retinopathy Network (DR-NET) was established [2]. This is a...

Simulated ocular surgery: pars plana vitrectomy and scleral buckling surgery

See also Simulated ocular surgery and Simulated ocular surgery - strabismus surgery In this second article on ocular surgery simulation, we will discuss how vitreoretinal surgery can be simulated using high tech virtual reality modalities such as the Eyesi, as...

Simulated ocular surgery

See also Simulated ocular surgery - strabismus surgery and Simulated ocular surgery: pars plana vitrectomy and scleral buckling surgery This is the first of a series of articles that will have three aims. Firstly, to demonstrate why simulated ocular surgery...

Corporate M&A pace gathers momentum

Intensifying franchise competition, maturing product development pipelines and looming loss of exclusivity spur renewed merger and acquisition (M&A) activity in the ophthalmics sector. Rod McNeil reviews recent deals and related strategic developments. AbbVie to acquire Allergan in $63 billion mega-combination,...